Literature DB >> 24958952

Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.

Julie M Akin1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 24958952      PMCID： PMC4062714          DOI： 10.1310/hpj4905-425

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  23 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 2.  Hepatotoxicity of chemotherapy.

Authors:  P D King; M C Perry
Journal:  Oncologist       Date:  2001

3.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

4.  A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.

Authors:  Robert S Mannel; Mark F Brady; Elise C Kohn; Parviz Hanjani; Masamichi Hiura; Roger Lee; Koen Degeest; David E Cohn; Bradley J Monk; Helen Michael
Journal:  Gynecol Oncol       Date:  2011-05-06       Impact factor: 5.482

5.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors:  Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-07       Impact factor: 3.333

6.  Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

Authors:  Gerasimos Aravantinos; George Fountzilas; Aristotelis Bamias; Irene Grimani; Spyridon Rizos; Haralabos P Kalofonos; Dimosthenis V Skarlos; Theofanis Economopoulos; Paris A Kosmidis; George P Stathopoulos; Evangelos Briasoulis; Dimitrios Pectasides; Epaminondas Samantas; Eleni Timotheadou; Christos Papadimitriou; Alexandros Papanikolaou; Adimchi Onyenadum; Pavlos Papakostas; Dimitrios Bafaloukos; Meletios A Dimopoulos
Journal:  Eur J Cancer       Date:  2008-08-06       Impact factor: 9.162

7.  Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.

Authors:  Y W Cheung; J C Cradock; B R Vishnuvajjala; K P Flora
Journal:  Am J Hosp Pharm       Date:  1987-01

Review 8.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

9.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

10.  Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.

Authors:  Dieter Kaag
Journal:  Lung Cancer       Date:  2012-11-04       Impact factor: 5.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.